Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

Todd Neale

February 08, 2021

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Features

The Cancer Patient Needing PCI Poses Conundrums for Care

Shelley Wood

January 14, 2020

News Features

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

Shelley Wood

April 30, 2019

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Features

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

Todd Neale

June 08, 2018

News Features

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

Caitlin E. Cox

May 02, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

Advertisement

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

The Cancer Patient Needing PCI Poses Conundrums for Care

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

The M Word: Is Routine Transfemoral PCI Defensible in 2018?

To RCT or Not to RCT? Impella Debate Pivots on How Best to Study Patients on the Brink of Death

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content